These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 10674266)
21. Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Vitagliano D; Portella G; Troncone G; Francione A; Rossi C; Bruno A; Giorgini A; Coluzzi S; Nappi TC; Rothstein JL; Pasquinelli R; Chiappetta G; Terracciano D; Macchia V; Melillo RM; Fusco A; Santoro M Oncogene; 2006 Aug; 25(39):5467-74. PubMed ID: 16785999 [TBL] [Abstract][Full Text] [Related]
22. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. Vasko V; Ferrand M; Di Cristofaro J; Carayon P; Henry JF; de Micco C J Clin Endocrinol Metab; 2003 Jun; 88(6):2745-52. PubMed ID: 12788883 [TBL] [Abstract][Full Text] [Related]
24. [Expression of BRAF V600E mutation in different thyroid lesions]. Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464 [TBL] [Abstract][Full Text] [Related]
25. Mutation of the PIK3CA gene in anaplastic thyroid cancer. García-Rostán G; Costa AM; Pereira-Castro I; Salvatore G; Hernandez R; Hermsem MJ; Herrero A; Fusco A; Cameselle-Teijeiro J; Santoro M Cancer Res; 2005 Nov; 65(22):10199-207. PubMed ID: 16288007 [TBL] [Abstract][Full Text] [Related]
26. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Garcia-Rostan G; Zhao H; Camp RL; Pollan M; Herrero A; Pardo J; Wu R; Carcangiu ML; Costa J; Tallini G J Clin Oncol; 2003 Sep; 21(17):3226-35. PubMed ID: 12947056 [TBL] [Abstract][Full Text] [Related]
27. N-ras mutation of thyroid tumor with special reference to the follicular type. Oyama T; Suzuki T; Hara F; Iino Y; Ishida T; Sakamoto A; Nakajima T Pathol Int; 1995 Jan; 45(1):45-50. PubMed ID: 7704243 [TBL] [Abstract][Full Text] [Related]
28. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma. Lam AK; Lo CY; Leung P; Lang BH; Chan WF; Luk JM Ann Surg Oncol; 2007 May; 14(5):1772-9. PubMed ID: 17195959 [TBL] [Abstract][Full Text] [Related]
29. Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens. Giordano TJ; Beaudenon-Huibregtse S; Shinde R; Langfield L; Vinco M; Laosinchai-Wolf W; Labourier E Hum Pathol; 2014 Jul; 45(7):1339-47. PubMed ID: 24830619 [TBL] [Abstract][Full Text] [Related]
30. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632 [TBL] [Abstract][Full Text] [Related]
31. Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours. Banito A; Pinto AE; Espadinha C; Marques AR; Leite V Clin Endocrinol (Oxf); 2007 Nov; 67(5):706-11. PubMed ID: 17651453 [TBL] [Abstract][Full Text] [Related]
32. Variability of Ha-ras (codon 12) proto-oncogene mutations in diverse thyroid cancers. Bouras M; Bertholon J; Dutrieux-Berger N; Parvaz P; Paulin C; Revol A Eur J Endocrinol; 1998 Aug; 139(2):209-16. PubMed ID: 9724079 [TBL] [Abstract][Full Text] [Related]
33. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland? Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212 [TBL] [Abstract][Full Text] [Related]
34. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289 [TBL] [Abstract][Full Text] [Related]
35. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Manenti G; Pilotti S; Re FC; Della Porta G; Pierotti MA Eur J Cancer; 1994; 30A(7):987-93. PubMed ID: 7946598 [TBL] [Abstract][Full Text] [Related]
37. p53 mutations in all stages of thyroid carcinomas. Zou M; Shi Y; Farid NR J Clin Endocrinol Metab; 1993 Oct; 77(4):1054-8. PubMed ID: 8408453 [TBL] [Abstract][Full Text] [Related]
38. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer. Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909 [TBL] [Abstract][Full Text] [Related]
39. Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumors. Challeton C; Bounacer A; Du Villard JA; Caillou B; De Vathaire F; Monier R; Schlumberger M; Suárez HG Oncogene; 1995 Aug; 11(3):601-3. PubMed ID: 7630645 [TBL] [Abstract][Full Text] [Related]
40. ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum. Garrett AP; Ng SW; Muto MG; Welch WR; Bell DA; Berkowitz RS; Mok SC Gynecol Oncol; 2000 Apr; 77(1):105-11. PubMed ID: 10739698 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]